Eisai Co., Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ESAIY Over the counter 2834 www.eisai.co.jp

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eisai Co., Ltd.

BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China - Feb 8th, 2026 11:07 pm
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China - Feb 8th, 2026 7:00 pm
Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump - Feb 8th, 2026 3:31 pm
Assessing Eisai (TSE:4523) Valuation After Mixed Share Price Momentum And LEQEMBI Expectations - Feb 8th, 2026 7:05 am
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 - Feb 6th, 2026 4:23 am
Eisai signs $388m deal for Japanese rights to Henlius’ anti-PD-1 mAb - Feb 5th, 2026 11:37 am
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan - Feb 5th, 2026 4:44 am
Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai - Feb 2nd, 2026 6:00 pm
Eisai: Canada's Drug Agency Recommendation Denies Canadians Safer Insomnia Treatments - Jan 29th, 2026 10:30 am
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab) - Jan 26th, 2026 2:13 pm
Will FDA’s Priority Review of At‑Home LEQEMBI IQLIK Dosing Change Biogen’s (BIIB) Narrative - Jan 26th, 2026 1:11 pm
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA - Jan 25th, 2026 7:48 pm
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review - Jan 25th, 2026 4:30 pm
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review - Jan 25th, 2026 4:30 pm
A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal - Jan 16th, 2026 9:07 am
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib - Jan 15th, 2026 9:35 am
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan - Jan 12th, 2026 5:30 am
What Biogen (BIIB)'s China Review for At‑Home LEQEMBI Injections Means For Shareholders - Jan 7th, 2026 6:10 am
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - Jan 7th, 2026 5:00 am
Assessing Biogen (BIIB) Valuation After China Accepts LEQEMBI Subcutaneous License Application - Jan 6th, 2026 7:13 am